LLY Earnings Date: Feb 3, 2027 (Estimated) — Eli Lilly and Company
NYSE · Healthcare · Drug Manufacturers - General
Updated
When is LLY's next earnings date?
Eli Lilly and Company (LLY) is expected to report Q4 2026 earnings on Wednesday, February 3, 2027 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $10.13 on revenue of $23.49B.
How did LLY do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Eli Lilly and Company posted EPS of $7.48 versus the $5.68 estimate, a beat of 31.7%. Revenue was $24.40B against a $22.58B estimate. The stock's 1-day post-earnings move was +6.6%.
How much does LLY stock move after earnings?
LLY beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.1% (up or down) in the day after earnings.
About Eli Lilly and Company
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
🤖 AI Earnings Analysis
Mounjaro and Zepbound drove 39% revenue growth to $24.4B, while Lilly raised 2026 guidance—an emphatic, demand-led result cementing its leadership in obesity and diabetes. EPS beat estimates by $1.80 at $7.48.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | 5.68 | 7.48 | +31.69% | $24.40B | ✅ Beat | +6.63% | — | — |
| 2026-08-05 | Q2 2026 | 6.40 | 8.38 | +39.43% | $22.97B | ✅ Beat | +4.86% | +8.90% | +4.13% |
| 2026-04-30 | Q1 2026 | 6.85 | 8.55 | +24.82% | $19.80B | ✅ Beat | +9.80% | +15.96% | +30.04% |
| 2026-02-04 | Q4 2025 | 6.96 | 7.54 | +8.33% | $19.30B | ✅ Beat | +10.33% | +2.15% | -1.85% |
| 2025-10-30 | Q3 2025 | 5.96 | 7.02 | +17.79% | $17.60B | ✅ Beat | +3.81% | +13.80% | +32.39% |
| 2025-08-07 | Q2 2025 | 5.60 | 6.31 | +12.68% | $15.56B | ✅ Beat | -14.14% | -11.51% | -2.35% |
| 2025-05-01 | Q1 2025 | 3.02 | 3.34 | +10.60% | $12.73B | ✅ Beat | -11.66% | -13.60% | -17.77% |
| 2025-02-06 | Q4 2024 | 5.08 | 5.32 | +4.72% | $13.53B | ✅ Beat | +3.35% | +3.66% | +3.43% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $24.24B total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Cardiometabolic Health | 81.5% | $19.76B | +50.0% | $7.41B | $9.21B | $11.34B | $13.18B |
| Oncology | 10.7% | $2.60B | +8.0% | $2.56B | $1.95B | $2.41B | $2.41B |
| Immunology | 5.9% | $1.44B | +5.3% | $1.19B | $1.09B | $1.26B | $1.36B |
| Neuroscience | 1.8% | $444.0M | +40.6% | $469.0M | $272.1M | $344.0M | $315.7M |
By region
Q3 FY26 · $24.40B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 62.0% | $15.14B | +33.9% | $8.49B | $10.81B | $11.30B | $12.88B |
| Europe | 18.3% | $4.46B | +27.5% | $2.39B | $2.57B | $3.50B | $3.10B |
| Non-US | 13.1% | $3.21B | +90.0% | $997.4M | $1.18B | $1.69B | $2.19B |
| CHINA | 3.9% | $947.0M | +69.0% | $450.8M | $465.9M | $560.4M | $473.9M |
| JAPAN | 2.7% | $648.0M | +16.8% | $402.2M | $521.0M | $554.7M | $654.1M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.